ClinicalTrials.gg
Not yet recruitingNCT07857421Updated Oct 5, 2026

AI-Based Wearable Monitoring (Glandy HYPER) for Antithyroid Drug Dose Adjustment in Graves' Disease

An interventional study of Glandy HYPER (AI-based monitoring software) and Methimazole in Hyperthyroidism, Graves Disease and Thyrotoxicosis, sponsored by THYROSCOPE INC.. Not yet recruiting at 2 sites in Germany. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by THYROSCOPE INC. · Not applicable, Interventional, and Treatment

How we know

Updated Oct 5, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
22 Years and older
Sex
All
01

Study summary

Graves' disease is the most common cause of hyperthyroidism and is usually treated with antithyroid drugs such as methimazole (MMI). The MMI dose is adjusted according to periodic blood tests, but individual responses vary, so some patients remain hyperthyroid longer than necessary while others become hypothyroid from overtreatment. Glandy HYPER is a CE-marked, AI-based software medical device that analyzes sleep heart rate data collected by a smartwatch, together with thyroid function test results, to provide daily information on thyrotoxicosis status. This exploratory, post-market, two-center, randomized, open-label study in Germany evaluates whether MMI dose adjustment supported by Glandy HYPER shortens the time to normalization of free T4 compared with standard care, and also assesses overtreatment, thyroid-related quality of life, and safety.

Read the detailed description

This is an exploratory, post-market, prospective, randomized, open-label, two-arm clinical study conducted at two sites in Frankfurt, Germany (protocol 01-01-DE-001). It evaluates the clinical utility, performance and safety of Glandy HYPER, a CE-marked (MDR Class IIa) AI-based software medical device, in supporting methimazole (MMI) dose adjustment in adults with newly diagnosed or persistent thyrotoxic Graves' disease.

After written informed consent at Visit 1 (screening, Day -14 to 0), participants are randomized 2:1 (intervention:control) using a computer-generated procedure in the secuTrial EDC system. All participants receive a smartwatch with a CE-certified ECG function (Apple Watch for iOS users, Samsung Galaxy Watch for Android users) and are trained in its use; they wear it during sleep (at least 3 hours) and record an ECG before bedtime. Patients already taking MMI must be able to stop it between Visit 1 and Visit 2. At Visit 2 (baseline, Day 0), participants with confirmed thyrotoxicosis (free T4) and available sleep heart rate data are registered and MMI is started. Follow-up visits take place at Weeks 4, 8 and 12 (Visits 3-5, each +/- 1 week) with routine blood tests (free T4, TSH, liver parameters, blood count); the ThyPRO-39 quality-of-life questionnaire is completed at Visits 2-5. Participation lasts approximately 14 weeks.

Intervention arm (n=20): The MMI starting dose is determined by a predefined algorithm based on the Visit 1 free T4 level relative to the upper limit of normal. Glandy HYPER provides a once-daily thyrotoxicosis status result. If a "non-hyperthyroid" result occurs on three or more occasions between scheduled visits, the treating physician decides on MMI dose adjustment based on the clinical and laboratory situation, taking the Glandy HYPER data into account, and may schedule an unscheduled visit for laboratory confirmation; an unscheduled visit replaces the next scheduled visit. At each visit, if free T4 is above the normal range, the dose follows the predefined dose criteria; if free T4 is within the normal range, the dose is determined by the physician.

Control arm (n=10): MMI is started and adjusted by the physician according to routine care. Wearable data are collected, but Glandy HYPER results are not disclosed to participants or physicians and are not used for clinical decisions.

Glandy HYPER provides decision support only, and all dose decisions are made by the treating physician. After completion of the study schedule, the performance of Glandy HYPER in detecting thyrotoxicosis is evaluated against the laboratory free T4-based thyroid status.

02

Conditions studied

  • Hyperthyroidism
  • Graves Disease
  • Thyrotoxicosis

Keywords

  • Glandy HYPER
  • Wearable device
  • Artificial intelligence
  • Methimazole
  • Antithyroid drug
  • Software as a medical device
  • Thyroid function
03

In context

Hyperthyroidism

113 studies on the registry are indexed under Hyperthyroidism; 28 are open to participants now.

This study's planned enrollment of 30 is below the median of 60 across 61 interventional studies indexed under Hyperthyroidism.

Browse Hyperthyroidism studies →

Lead sponsor

THYROSCOPE INC. is the lead sponsor of 4 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults (>= 22 years) newly diagnosed with Graves' disease or currently in a thyrotoxic state despite ongoing treatment
  • Diagnosis of Graves' disease based on: primary hyperthyroidism confirmed by thyroid function test (TFT); positive TSH-receptor antibody (TRAb); and clinical presentation consistent with Graves' disease
  • At screening (Visit 1), individuals who have received an explanation of and are able to use Glandy HYPER
  • Individuals who voluntarily decide to participate in the clinical study and have signed the form

Exclusion criteria

Exclusion Criteria:

  • Patients who are taking or require propylthiouracil (PTU) due to intolerance to methimazole (MMI), pregnancy, or other reasons
  • Patients currently on MMI therapy if MMI cannot be discontinued from Visit 1 (screening) until Visit 2
  • Individuals with cardiac disorders such as arrhythmia, heart failure, etc.
  • Individuals currently taking medications that affect heart rate, including all types of antiarrhythmic drugs, antihistamines, etc. (intermittent use of short-acting beta-blockers to relieve hyperthyroid symptoms is permitted)
  • Pregnant or breastfeeding women
  • Patients who plan to become pregnant or do not agree to use appropriate methods (pregnancy testing is required for women of )
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Intervention arm (Glandy HYPER-supported)

    Participants wear a smartwatch and use the Glandy HYPER app, which provides a once-daily thyrotoxicosis status result based on sleep heart rate data. Methimazole (MMI) is started at Visit 2 at a dose determined by a predefined algorithm based on the Visit 1 free T4 level. If a "non-hyperthyroid" result occurs on three or more occasions between scheduled visits, the treating physician decides on MMI dose adjustment based on the clinical and laboratory situation, taking the Glandy HYPER data into account, and may schedule an unscheduled visit for laboratory confirmation. All dose decisions are made by the treating physician.

    Device: Glandy HYPER (AI-based monitoring software) · Drug: Methimazole

  • Active comparator
    Control arm (Standard care)

    Participants wear the same smartwatch; wearable data are collected, but Glandy HYPER results are not disclosed to participants or physicians and are not used for clinical decisions. Methimazole (MMI) is started at Visit 2 and adjusted by the physician according to routine clinical care based on blood tests at scheduled visits (every 4 weeks +/- 1 week); the visit interval may be shortened at the physician's discretion.

    Drug: Methimazole

Interventions

  • DeviceGlandy HYPER (AI-based monitoring software)

    CE-marked (MDR Class IIa) software as a medical device (mobile app) that analyzes sleep heart rate data collected by a smartwatch, together with thyroid function test results (free T4, TSH), to provide information on thyrotoxicosis status. In the intervention arm, the once-daily results are available to the treating physician to support methimazole dose adjustment.

  • Oral antithyroid drug for the treatment of hyperthyroidism. Intervention arm: starting dose per a predefined free T4-based algorithm; subsequent adjustments are decided by the treating physician taking Glandy HYPER results into account. Control arm: starting dose and adjustments per the physician's routine clinical judgment.

06

What researchers measure

Primary outcomes

  1. Time to First Normal Free T4 Level

    Time (days) from initiation of antithyroid medication (methimazole) at Visit 2 to the first laboratory confirmation of a serum free T4 (fT4) level within the site-specific normal range (Site 1: 0.82-1.77 ng/dL; Site 2: 0.93-1.67 ng/dL), assessed at scheduled and unscheduled clinic visits and compared between the intervention and control arms.

    Time frame: From Visit 2 (Day 0) to Visit 5 (Week 12 +/- 1 week)

Secondary outcomes

  1. Number of Occurrences of Free T4 Below the Lower Limit of Normal

    Number of clinic visits (scheduled or unscheduled) per participant at which serum free T4 is below the site-specific lower limit of normal (Site 1: \<0.82 ng/dL; Site 2: \<0.93 ng/dL), as an indicator of overtreatment (iatrogenic hypothyroidism).

    Time frame: From Visit 2 (Day 0) to Visit 5 (Week 12 +/- 1 week)

  2. Change From Baseline in Thyroid-Related Quality of Life (ThyPRO-39)

    Thyroid-related quality of life is assessed with the self-administered ThyPRO-39 questionnaire (Thyroid-Related Patient-Reported Outcome, 39-item short version) at each clinic visit. Scale scores, including the composite quality-of-life impact score, range from 0 to 100, with higher scores indicating worse quality of life. Scores at each visit and change from baseline (Visit 2) are reported.

    Time frame: Baseline (Visit 2, Day 0), Week 4 (Visit 3), Week 8 (Visit 4) and Week 12 (Visit 5); visits +/- 1 week

  3. Number of Participants With Procedure-Related Serious Incidents

    Serious incidents (as defined in Regulation (EU) 2017/745) assessed by the investigator as related to the study device or study procedures, coded using IMDRF terminology.

    Time frame: From informed consent (Visit 1) to Visit 5 (Week 12 +/- 1 week)

Other outcomes

  1. Diagnostic Performance of Glandy HYPER for Detecting Thyrotoxicosis

    Agreement between the Glandy HYPER output (thyrotoxic vs. non-thyrotoxic) and the thyroid status determined by laboratory free T4 (site-specific reference ranges) at each clinic visit with a blood test, expressed as sensitivity, specificity, positive predictive value and negative predictive value with 95% confidence intervals, pooled across both arms. Evaluated after completion of the study schedule.

    Time frame: At each clinic visit with a blood test from Visit 3 (Week 4) to Visit 5 (Week 12 +/- 1 week)

07

Study locations

2 sites
  • University Hospital Frankfurt, Centre for Internal Medicine, Medical Department 1
    Frankfurt am Main, Hesse 60590, Germany
    • Jörg Bojunga, Prof. Dr. med. · Principal investigator
  • Endokrinologikum Frankfurt am Main
    Frankfurt am Main, Hesse 60596, Germany
    • Alexander Mann, Prof. Dr. med. · Principal investigator
08

References and documents

Individual participant data

Plan to share: No — No individual participant data will be shared. The final clinical study report (with personal data redacted) and a lay summary will be made publicly available on ClinicalTrials.gov.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Jun 2027, 8 months later.

Of 15 interventional studies with no phase under Hyperthyroidism, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 46. This study's planned 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2026
First posted
Oct 5, 2026
StartEst.
Oct 20, 2026
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jul 31, 2027
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07857421
Lead sponsor
THYROSCOPE INC.
Responsible party
Sponsor
First posted
Oct 5, 2026
Start date
Oct 20, 2026 (estimated)
Primary completion
Jun 30, 2027 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Oct 5, 2026

Study contacts

Clinical Research Team, THYROSCOPE INC.
Contact
research@thyroscope.com
+82 52 264 4154
Jörg Bojunga, Prof. Dr. med.
principal investigator · Universitätsmedizin Frankfurt (University Hospital Frankfurt)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion